Download PDF
Clin Colon Rectal Surg 2012; 25(02): 090-096
DOI: 10.1055/s-0032-1313779
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Endoscopic and Surgical Management of Hereditary Nonpolyposis Colorectal Cancer

Rebeccah B. Baucom
1   Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.
,
Paul E. Wise
1   Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.
› Author Affiliations
Further Information

Publication History

Publication Date:
30 May 2012 (online)

    Permissions and Reprints

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome is a disease characterized by autosomal dominant clustering of colorectal cancer (CRC) as well as other cancers. It is critical for clinicians and surgeons caring for patients with HNPCC to be familiar with their management related to CRC. Based on retrospective studies, screening colonoscopy is recommended every 1 to 2 years beginning at age 20 to 25, or 10 years younger than the earliest CRC in the family (whichever is earlier). HNPCC patients with colon cancer should be considered for total abdominal colectomy rather than a more limited segmental colon resection due to the increased risk of metachronous neoplasia associated with the condition. Rectal cancer in HNPCC has not been well studied, but discussions with the patient regarding surgical management should weigh the risks of metachronous CRC with the morbidity and quality of life issues associated with proctocolectomy. Regardless of the procedure, a patient with HNPCC requires close postoperative endoscopic surveillance of any remaining at-risk mucosa. In terms of chemoprevention, aspirin has been shown to be effective in preventing colorectal neoplasia in prospective trials and should be considered in patients who do not have a contraindication to the drug. Trials for other chemopreventative agents in HNPCC are ongoing. As more is learned about particular genotype–phenotype correlations with Lynch syndrome, this will likely affect surgical decision making. Despite all of these efforts in the management of patients with HNPCC or Lynch syndrome, incident CRCs still occur, thus reinforcing the need for further studies to better understand the optimal management of these patients.

Keywords

HNPCC - hereditary nonpolyposis colorectal cancer - Lynch syndrome - colon cancer - colorectal cancer - hereditary cancer syndrome
 

  • References

  • 1 Kalady MF, McGannon E, Vogel JD, Manilich E, Fazio VW, Church JM. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. Ann Surg 2010; 252 (3) 507-511 , discussion 511–513
    PubMedGoogle Scholar
  • 2 Kalady MF. Surgical management of hereditary nonpolyposis colorectal cancer. Adv Surg 2011; 45: 265-274
    CrossrefPubMedGoogle Scholar
  • 3 Vasen HF, Watson P, Mecklin JP , et al. New clinical criteria for hereditary nonpolyposis colorectal cancer proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999; 116: 1453-1456
    CrossrefPubMedGoogle Scholar
  • 4 Hampel H, Frankel WL, Martin E , et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26 (35) 5783-5788
    CrossrefPubMedGoogle Scholar
  • 5 Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348 (10) 919-932
    CrossrefPubMedGoogle Scholar
  • 6 Vasen HF, Abdirahman M, Brohet R , et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 2010; 138 (7) 2300-2306
    CrossrefPubMedGoogle Scholar
  • 7 Herráiz M, Muñoz-Navas M. Recognition and management of hereditary colorectal cancer syndromes. Rev Esp Enferm Dig 2009; 101 (2) 125-132
    PubMedGoogle Scholar
  • 8 Natarajan N, Watson P, Silva-Lopez E, Lynch HT. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum 2010; 53 (1) 77-82
    CrossrefPubMedGoogle Scholar
  • 9 Rodríguez-Bigas MA, Vasen HF, Pekka-Mecklin J , et al; International Collaborative Group on HNPCC. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. Ann Surg 1997; 225 (2) 202-207
    CrossrefPubMedGoogle Scholar
  • 10 Järvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995; 108 (5) 1405-1411
    CrossrefPubMedGoogle Scholar
  • 11 Järvinen HJ, Aarnio M, Mustonen H , et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118 (5) 829-834
    CrossrefPubMedGoogle Scholar
  • 12 Grover S, Syngal S. Risk assessment, genetic testing, and management of Lynch syndrome. J Natl Compr Canc Netw 2010; 8 (1) 98-105
    PubMedGoogle Scholar
  • 13 Lynch PM. Prevention of colorectal cancer in high-risk populations: the increasing role for endoscopy and chemoprevention in FAP and HNPCC. Digestion 2007; 76 (1) 68-76
    CrossrefPubMedGoogle Scholar
  • 14 East JE, Suzuki N, Stavrinidis M, Guenther T, Thomas HJ, Saunders BP. Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer. Gut 2008; 57 (1) 65-70
    CrossrefPubMedGoogle Scholar
  • 15 Lecomte T, Cellier C, Meatchi T , et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol 2005; 3 (9) 897-902
    CrossrefPubMedGoogle Scholar
  • 16 Hurlstone DP, Karajeh M, Cross SS , et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective “back-to-back” endoscopic study. Am J Gastroenterol 2005; 100 (10) 2167-2173
    CrossrefPubMedGoogle Scholar
  • 17 Vasen HF, Möslein G, Alonso A , et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44 (6) 353-362
    CrossrefPubMedGoogle Scholar
  • 18 Parry S, Win AK, Parry B , et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60 (7) 950-957
    CrossrefPubMedGoogle Scholar
  • 19 Celentano V, Luglio G, Antonelli G, Tarquini R, Bucci L. Prophylactic surgery in Lynch syndrome. Tech Coloproctol 2011; 15 (2) 129-134
    PubMedGoogle Scholar
  • 20 de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P , et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 2003; 52: 1752-1755
    CrossrefPubMedGoogle Scholar
  • 21 Van Dalen R, Church J, McGannon E, Fay S, Burke C, Clark B. Patterns of surgery in patients belonging to Amsterdam-positive families. Dis Colon Rectum 2003; 46 (5) 617-620
    CrossrefPubMedGoogle Scholar
  • 22 Olschwang S, Laurent-Puig P, Eisinger F, Millat B. An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome. Gut 2005; 54 (1) 169
    PubMedGoogle Scholar
  • 23 Bleiker EM, Menko FH, Taal BG , et al. Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology 2005; 128 (2) 280-287
    CrossrefPubMedGoogle Scholar
  • 24 Lee JS, Petrelli NJ, Rodriguez-Bigas MA. Rectal cancer in hereditary nonpolyposis colorectal cancer. Am J Surg 2001; 181 (3) 207-210
    CrossrefPubMedGoogle Scholar
  • 25 Jenkins MA. Role of MSH6 and PMS2 in the DNA mismatch repair process and carcinogenesis. Surg Oncol Clin N Am 2009; 18 (4) 625-636
    CrossrefPubMedGoogle Scholar
  • 26 Hampel H, Frankel WL, Martin E , et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352 (18) 1851-1860
    CrossrefPubMedGoogle Scholar
  • 27 Lynch PM. The hMSH2 and hMLH1 genes in hereditary nonpolyposis colorectal cancer. Surg Oncol Clin N Am 2009; 18 (4) 611-624
    CrossrefPubMedGoogle Scholar
  • 28 Bao F, Panarelli NC, Rennert H, Sherr DL, Yantiss RK. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol 2010; 34 (12) 1798-1804
    CrossrefPubMedGoogle Scholar
  • 29 Choi MY, Lauwers GY, Hur C, Willett CG, Chung DC. Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys 2007; 68 (5) 1584
    PubMedGoogle Scholar
  • 30 Ondrejka SL, Schaeffer DF, Jakubowski MA, Owen DA, Bronner MP. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?. Am J Surg Pathol 2011; 35 (9) 1327-1330
    CrossrefPubMedGoogle Scholar
  • 31 Heijink DM, de Vries EG, Koornstra JJ , et al. Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. Crit Rev Oncol Hematol 2011; 80 (2) 264-277
    CrossrefPubMedGoogle Scholar
  • 32 Burn J, Bishop DT, Mecklin JP , et al; CAPP2 Investigators. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008; 359 (24) 2567-2578
    CrossrefPubMedGoogle Scholar
  • 33 Burn J, Gerdes AM, Macrae F , et al; CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378 (9809) 2081-2087
    CrossrefPubMedGoogle Scholar
  • 34 Rijcken FE, Hollema H, van der Zee AG, van der Sluis T, Boersma-van Ek W, Kleibeuker JH. Sulindac treatment in hereditary non-polyposis colorectal cancer. Eur J Cancer 2007; 43 (8) 1251-1256
    CrossrefPubMedGoogle Scholar
  • 35 López-Ramos C, Castells A. Chemoprevention in the Lynch syndrome: what can we do?. Gastroenterology 2009; 137 (2) 730-732
    CrossrefPubMedGoogle Scholar
  • 36 Cats A, Kleibeuker JH, van der Meer R , et al. Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 1995; 87 (8) 598-603
    CrossrefPubMedGoogle Scholar
  • 37 Kleibeuker JH, Cats A, van der Meer R, Lapré JA, de Vries EG. Calcium supplementation as prophylaxis against colon cancer?. Dig Dis 1994; 12 (2) 85-97
    CrossrefPubMedGoogle Scholar
  • 38 Strate LL, Syngal S. Hereditary colorectal cancer syndromes. Cancer Causes Control 2005; 16 (3) 201-213
    CrossrefPubMedGoogle Scholar
  • 39 Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998; 129 (10) 787-796
    CrossrefPubMedGoogle Scholar